Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In a bid to expand its oncology pipeline, biopharmaceutical company Gilead Sciences Inc. ( GILD - Analyst Report ) inked a definitive agreement to buy a Canada-based drug development company, YM BioSciences Inc. ( ) for $2.95 per share. The all-cash deal, already cleared by the Board of Directors at YM BioSciences, is worth approximately $510 million.
The closure of the deal is dependant on the approval of the stockholders of YM BioSciences along with the satisfaction of certain other customary conditions. Gilead expects to close the acquisition in the first quarter of 2013. The offer price of $2.95 per share represents a premium of 81% over YM BioSciences’ closing price of $1.63 on December 11 2012.
As per the terms of the deal, each shareholder of YM BioSciences will be eligible to receive $2.95 for each share in cash. Moreover, holders of warrants and stock options will be eligible to receive the difference between the offer price of the deal and the exercise price of the warrant or stock option in cash.
On completion of the deal, Gilead’s oncology pipeline will be strengthened by the addition of CYT387, which is YM BioSciences’ lead candidate. CYT387 has completed phase I/II studies for the myelofibrosis indication. The candidate is expected to be moved into phase III studies for the same indication in the second half of 2013. Gilead intends to evaluate CYT387 in other oncology indications as well, once the candidate becomes part of its pipeline.
Currently, the lead oncology candidate at Gilead is idelalisib (formerly GS-1101). The candidate, added to Gilead’s pipeline through its 2011 acquisition of Calistoga Pharmaceuticals, is under development for the chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma indications. Another oncology candidate at Gilead is simtuzumab (formerly GS- 6624). The candidate, added to Gilead’s pipeline through its 2010 acquisition of Arresto Biosciences, is being evaluated in multiple oncology indications.
Our Recommendation
We currently have a long-term Neutral recommendation on Gilead. The stock carries a Zacks #3 Rank (Hold) in the short run. Another biopharmaceutical company, Questcor Pharmaceuticals, Inc. ( QCOR - Snapshot Report ) carries a Zacks #2 Rank (Buy) in the short run.
We have a Neutral stance on YM BioSciences. The stock carries a Zacks #2 Rank (Buy) in the short run.
Read the full reports :
Analyst Report on GILD
Snapshot Report on QCOR